2. SYNOPSIS

<table>
<thead>
<tr>
<th>Name of Sponsor/Company</th>
<th>Individual Study Table Referring to Part of the Dossier</th>
</tr>
</thead>
<tbody>
<tr>
<td>McNeil Consumer Products Company</td>
<td>(For National Authority Use Only)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name of Finished Product:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume:</td>
</tr>
<tr>
<td>Page:</td>
</tr>
</tbody>
</table>


**Investigators:**

**Study Centers:**

**Publication (Reference):**

**Study Period:**

**Date of first enrollment:**

**Date of last completed:**

**Phase of Development:**

**Objective:**

**Methodology:** Randomized, Open-label, Multicenter, Parallel

Children with low fever (101-102.5°F orally, or 102-103.5°F rectally) received IBU 5 mg/kg. Children with high fever (> 102.5-104.5°F orally, or > 103.5-105.5°F rectally) received IBU 10 mg/kg.

**Number of Subjects (planned and analyzed):** 71 subjects were included in the efficacy analysis and 83 subjects were included in the safety analysis. In the ibuprofen 5 mg/kg tablet group, 18 subjects were included in the efficacy analysis and 20 subjects in the safety analysis. In the ibuprofen 5 mg/kg suspension group, 16 subjects were included in the efficacy analysis and 19 subjects in the safety analysis. In the ibuprofen 10 mg/kg tablet group, 18 subjects were included in the efficacy analysis and 22 subjects in the safety analysis. In the ibuprofen 10 mg/kg suspension group, 19 subjects were included in the efficacy analysis and 22 subjects in the safety analysis.
Report 293A and Report 1475
Protocol 91-113

<table>
<thead>
<tr>
<th>Name of Sponsor/Company</th>
<th>Individual Study Table Referring to Part of the Dossier</th>
<th>(For National Authority Use Only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>McNeil Consumer Products Company</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Test Product, Dose and Mode of Administration, Batch Number:**
- Ibuprofen 5 mg/kg, tablet (chewable) oral
- Ibuprofen 5 mg/kg, suspension oral
- Ibuprofen 10 mg/kg, tablet (chewable) oral
- Ibuprofen 10 mg/kg, suspension oral

**Duration of Treatment:** This was a single-dose study.

**Summary - Conclusions**

**Efficacy Results:** In the ibuprofen 5 mg/kg tablet group, there were 11 females and 9 males. In the ibuprofen 5 mg/kg suspension group, there were 9 females and 10 males. In the ibuprofen 10 mg/kg tablet group, there were 14 females and 8 males. In the ibuprofen 10 mg/kg suspension group, there were 6 females and 16 males.

TEMPDIFF (temperature difference from baseline) (least squares mean): At 7h, 10 mg/kg tablets – 1.60, 10 mg/kg susp 2.63, p=0.005; at 8h: 10 mg/kg tablets 1.39, 10 mg/kg susp 2.11, p=0.05. 8 h SUMDIFF (sum of differences from baseline in temperature) (least squares mean): 5 mg/kg tablets – 13.86, 5 mg/kg susp – 15.09, p=NS, 10 mg/kg tablets –
Name of Sponsor/Company: McNeil Consumer Products Company

Name of Finished Product: Volume:

Name of Active Ingredient: ibuprofen

<table>
<thead>
<tr>
<th>Individual Study Table Referring to Part of the Dossier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page:</td>
</tr>
</tbody>
</table>

18.87, 10 mg/kg susp – 21.78, p=NS. MAXDIFF (maximum difference from baseline in temperature) (least squares mean): 5 mg/kg tablets - 3.00, 5 mg/kg susp - 2.98, p=NS, 10 mg/kg tablets - 4.02, 10 mg/kg susp - 3.90, p=NS. Mean total time of temperature reduction of ≥ 1°F (h): 5 mg/kg tablets – 5.94, 5 mg/kg susp - 6.39, p=NS, 10 mg/kg tablets – 5.61, 10 mg/kg susp - 6.85, p=0.023. Mean number of hours of an improved clinical response (h): 5 mg/kg tablets - 1.87, 5 mg/kg susp – 1.99, p=NS, 10 mg/kg tablets – 1.98, 10 mg/kg susp - 2.37, p=NS. Mean global evaluation (5-point categorical scale): 5 mg/kg tablets - 2.74, 5 mg/kg susp - 3.00, p=NS, 10 mg/kg tablets - 2.57, 10 mg/kg susp - 2.87, p=NS. Number of subjects using rescue medication: 5 mg/kg tablets - 8, 5 mg/kg susp - 3, 10 mg/kg tablets - 7.

Safety Results: AEs reported in more than 1 subject: tablet- urinary tract infection (2), viral illness/syndrome (3). There were no AEs related to study drug. One subject was hospitalized for shigallosis. One subject who vomited the study medication was discontinued, and 1 subject discontinued due to an adverse reaction to amoxicillin.

PK Results: Mean Vd/F (apparent volume of distribution per fraction of drug absorbed, L/kg): low fever (5 mg/kg tablet-0.247, 5 mg/kg susp-0.177), high fever (10 mg/kg tablet-0.205, 10 mg/kg susp-0.174). Mean kₐ (first order rate constant for drug absorption, 1/h): low fever (5 mg/kg tablet-1.782, 5 mg/kg susp-5.441), high fever (10 mg/kg tablet-2.496, 10 mg/kg susp-4.182). Mean β (1/h): low fever (5 mg/kg tablet-0.148, 5 mg/kg susp-0.363), high fever (10 mg/kg tablet-0.189, 10 mg/kg susp-0.360). Mean Kₑ₁ (first order rate constant for drug elimination, 1/h): low fever (5 mg/kg tablet-0.459, 5 mg/kg susp-0.488), high fever (10 mg/kg tablet-0.483, 10 mg/kg susp-0.497). Mean Kₑ₀ (first order rate constant for drug loss from effect site, 1/h): low fever (5 mg/kg tablet-0.813, 5 mg/kg susp-0.739), high fever (10 mg/kg tablet-0.830, 10 mg/kg susp-0.383). Mean EC₅₀ (drug concentration producing 50% of maximum effect, µg/mL): low fever (5 mg/kg tablet-10.507, 5 mg/kg susp-7.370), high fever (10 mg/kg tablet-12.662, 10 mg/kg susp-8.254). Mean gamma (sigmoidicity factor of sigmoid Emax and inhibition functions): low fever (5 mg/kg tablet-2.086, 5 mg/kg susp-2.888), high fever (10 mg/kg tablet-2.214, 10 mg/kg susp-2.393). Mean tₐₙₐ (absorption lag time, h): low fever (5 mg/kg tablet-0.16, 5 mg/kg
**Name of Sponsor/Company**: McNeil Consumer Products Company

**Name of Finished Product:**

**Name of Active Ingredient:** ibuprofen

**Individual Study Table Referring to Part of the Dossier**

<table>
<thead>
<tr>
<th>Volume:</th>
<th>Page:</th>
</tr>
</thead>
</table>

susp-0.14), high fever (10 mg/kg tablet-0.20, 10 mg/kg susp-0.13).

**Conclusions:** Conclusions were not provided in the clinical study report.

**Date of the Report:** April 1994